{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'setting when olaparib maintenance treatment is given after one line of platinum chemotherapy', 'for a duration of 2 years.', 'Hematological toxicity', 'Anaemia and other haematological toxicities are generally low grade (CTCAE Grade 1 or 2)', 'however, there are reports of CTCAE Grade 3 and higher events. Anaemia was the most', 'common CTCAE Grade >3 adverse reaction reported in clinical studies with first onset', 'generally reported in the first 3 months of treatment. An exposure response relationship', 'between olaparib and decreases in haemoglobin has been demonstrated. In clinical studies', 'with olaparib monotherapy the incidence of CTCAE Grade >2 shifts (decreases) from baseline', 'in haemoglobin was 23%, absolute neutrophils 19%, platelets 6%, lymphocytes 29% and', 'leucocytes 20% (all % approximate).', 'The incidence of elevations in mean corpuscular volume from low or normal at baseline to', 'above the ULN was approximately 55%. Levels appeared to return to normal after treatment', 'discontinuation and did not appear to have any clinical consequences.', 'Baseline testing, followed by monthly monitoring of complete blood counts is recommended', 'for the first 12 months of treatment with olaparib, and periodically after this time to monitor', 'for clinically significant changes in any parameter during treatment which may require dose', 'interruption or reduction and/or further treatment.', 'Other laboratory findings', 'In clinical studies with olaparib the incidence of CTCAE Grade >2 shifts (elevations) from', 'baseline in blood creatinine was approximately 11%. Data from a double-blind placebo', 'controlled study showed median increase up to 23% from baseline remaining consistent over', 'time and returning to baseline after treatment discontinuation, with no apparent clinical', 'sequelae. The increase in blood creatinine level might be explained by inhibition of renal', 'transporters such as OCT2, MATE1 and MATE2K by olaparib, as blood creatinine levels', 'were found to return to baseline after treatment discontinuation. 90% of patients had', 'creatinine values of CTCAE Grade 0 at baseline and 10% were CTCAE Grade 1 at baseline.', 'Nausea and vomiting', 'Nausea was generally reported very early, with first onset within the first month of olaparib', 'treatment in the majority of patients. Vomiting was reported early, with first onset within the', 'first two months of olaparib treatment in the majority of patients. Both nausea and vomiting', 'were reported to be intermittent for the majority of patients.', 'Combination studies', 'Safety data from studies in which olaparib has been administered in combination with other', \"agents are discussed in the Investigator's Brochure. The degree of bone marrow suppression\", 'observed in some patients in the combination studies has however been greater than would be', '27(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'expected with the chemotherapy agent alone, as per label information. Myelotoxicity has been', 'observed in studies evaluating olaparib with the following combination therapies: DTIC;', 'carboplatin; paclitaxel; carboplatin + paclitaxel; gemcitabine; topotecan; cisplatin;', 'doxorubicin, cisplatin + gemcitabine; or irinotecan.', 'The principal hematological toxicities observed have been neutropenia, thrombocytopenia and', 'anemia. These findings are consistent with pre-clinical findings [72, 76-78, 94].', '28(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}